The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000621314p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
28/04/2026
Date registered
Help: Date registered
20/05/2026
Date last updated
Help: Date last updated
20/05/2026
Date data sharing statement initially provided
Help: Data sharing statement date
20/05/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Voyant Versus Diathermy for Haemostasis in Breast Cancer Surgery: A Randomised Controlled Trial
Scientific title
Effect of Voyant Versus Diathermy for Haemostasis on post-surgical drainage and seroma in Breast Cancer Surgery: A Randomised Controlled Trial
Additional trial identifiers [1] 317126 0
Nil
Universal Trial Number (UTN)
Trial acronym
VIBE
Related trial records

Health condition
Health condition(s) studied:
Breast Cancer 341684 0
Condition category
Condition code
Cancer 337774 337774 0 0
Breast
Surgery 337775 337775 0 0
Surgical techniques

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Arm A: Voyant Intelligent Energy System
Participants in this arm will undergo planned breast surgery using the Voyant Intelligent Energy System for tissue dissection, haemostasis and vessel sealing during the main operative phase of surgery. Voyant is an advanced bipolar energy device that differs from standard care diathermy by using controlled bipolar energy designed for vessel sealing and tissue division rather than conventional monopolar or bipolar electrosurgery alone. The procedure duration is expected to be approximately 1–3 hours, depending on the type and extent of surgery. The intervention will be delivered by the treating breast surgeon and/or appropriately trained surgical team members. Adherence will be monitored through operation notes, theatre documentation and study case report forms recording the device used.
Intervention code [1] 333890 0
Treatment: Devices
Intervention code [2] 333891 0
Treatment: Surgery
Description of the comparator or control
Arm B: Standard care diathermy
Participants in this arm will undergo planned breast surgery using standard monopolar and/or bipolar diathermy for tissue dissection and haemostasis during the main operative phase of surgery. This differs from the intervention arm, which uses the Voyant Intelligent Energy System, an advanced bipolar vessel-sealing device. The procedure duration is expected to be approximately 1–3 hours, depending on the type and extent of surgery. The intervention will be delivered by the treating breast surgeon and/or appropriately trained surgical team members. Adherence will be monitored through operation notes, theatre documentation and study case report forms recording the device used.
Control group
Active

Outcomes
Primary outcome [1] 345223 0
Time to drain removal (Days)
Timepoint [1] 345223 0
Daily from Day 1 post-operative until removal and day 30 Follow up
Primary outcome [2] 345224 0
Total drain output
Timepoint [2] 345224 0
Daily from Day 1 post-operative until removal and day 30 follow-up
Primary outcome [3] 345225 0
Seroma requiring aspiration
Timepoint [3] 345225 0
Day 30 follow-up
Secondary outcome [1] 460992 0
Operative time
Timepoint [1] 460992 0
Day of surgery
Secondary outcome [2] 460993 0
Intraoperative blood loss
Timepoint [2] 460993 0
Intraoperative (at end of surgery)
Secondary outcome [3] 460994 0
Return to the operating theatre
Timepoint [3] 460994 0
30 day follow-up
Secondary outcome [4] 460995 0
Wound infection
Timepoint [4] 460995 0
Daily from post-operative up until and including day 30.
Secondary outcome [5] 460996 0
Pain scores
Timepoint [5] 460996 0
At timepoints- 24 hours, 48 hours, and day 5 after surgery.
Secondary outcome [6] 460997 0
30-day readmission
Timepoint [6] 460997 0
At the 30-day follow-up
Secondary outcome [7] 460998 0
Lymphedema
Timepoint [7] 460998 0
At the 30 day follow-up
Secondary outcome [8] 460999 0
Length of hospital stay
Timepoint [8] 460999 0
At the 30 day follow-up
Secondary outcome [9] 461000 0
30-day quality of life
Timepoint [9] 461000 0
30 days after surgery

Eligibility
Key inclusion criteria
Adults greater or equal to 18 years of age
Undergoing unilateral or bilateral mastectomy
Able to provide informed consent
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Simultaneous major reconstructive procedures (e.g. free flap)
Prior ipsilateral axillary surgery
Known bleeding disorders or contraindications to stopping anticoagulation
Active infection or pregnancy

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation was concealed using a central computer-generated randomisation process, accessed only after participant eligibility was confirmed and consent obtained. Investigators enrolling participants were unaware of the upcoming treatment allocation at the time of enrolment.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
1:1 randomisation in a block of 6 by computer-generated
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW

Funding & Sponsors
Funding source category [1] 321710 0
Hospital
Name [1] 321710 0
Calvary Mater Newcastle
Country [1] 321710 0
Australia
Primary sponsor type
Hospital
Name
Calvary Mater Newcastle
Address
Country
Australia
Secondary sponsor category [1] 324540 0
None
Name [1] 324540 0
None
Address [1] 324540 0
Country [1] 324540 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 320242 0
Hunter New England Human Research Ethics Committee
Ethics committee address [1] 320242 0
Ethics committee country [1] 320242 0
Australia
Date submitted for ethics approval [1] 320242 0
24/04/2026
Approval date [1] 320242 0
Ethics approval number [1] 320242 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149866 0
Dr David Logan
Address 149866 0
Calvary Mater Newcastle, Edith St, Waratah NSW 2298
Country 149866 0
Australia
Phone 149866 0
+61 4077340275
Fax 149866 0
Email 149866 0
Contact person for public queries
Name 149867 0
Natalie Lott
Address 149867 0
Calvary Mater Newcastle, Edith St, Waratah NSW 2298
Country 149867 0
Australia
Phone 149867 0
+61 0418215968
Fax 149867 0
Email 149867 0
Contact person for scientific queries
Name 149868 0
Natalie Lott
Address 149868 0
Calvary Mater Newcastle, Edith St, Waratah NSW 2298
Country 149868 0
Australia
Phone 149868 0
+61 0418215968
Fax 149868 0
Email 149868 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.